Table 2. Characteristics of the study population.
| No. of patients, n | 152 |
| Mean age at diagnosis ± SD, years | 5.1456±3.41 |
| Sex, n (%) | |
| Female | 65 (42.76) |
| Male | 87 (57.23) |
| Risk group, n (%) | |
| Standard | 56 (40.57) |
| High | 56 (40.57) |
| Very high | 26 (18.84) |
| Treatment protocol, n (%) | |
| LAL-SHOP 94/99 | 65 (43.05) |
| LAL-SHOP 2005 | 86 (56.95) |
| MTX dose in consolidation, n (%) | |
| 3 g/m2 | 73 (48.34) |
| 5 g/m2 | 78 (51.66) |
| Toxicity during induction therapy, n (%) | |
| Any toxicity | 79 (57.66) |
| Hepatic (Grade 2–4) | 45 (32.84) |
| Vomits (Grade 2–4) | 36 (26.28) |
| Diarrhea (Grade 2–4) | 16 (11.67) |
| Mucositis (Grade 2–4) | 29 (21.17) |
| Hyperbilirubinemia (Grade 1–4) | 21 (15.32) |
| Renal (Grade 1–4) | 5 (3.65) |
| Toxicity during consolidation therapy, n (%) | |
| Any toxicity | 71 (54.61) |
| Hepatic (Grade 2–4) | 39 (30) |
| Vomits (Grade 2–4) | 31 (23.85) |
| Diarrhea (Grade 2–4) | 9 (6.92) |
| Mucositis (Grade 2–4) | 14 (10.77) |
| Hyperbilirubinemia (Grade 1–4) | 11 (8.46) |
| Renal (Grade 1–4) | 13 (10) |
| MTX concentration in plasma a, n (%) | |
| Higher than 0.2 uM at 72 h | 51 (36.17) |
a
MTX levels were considered high if the concentration was over 0.2 µM at 72 h.